Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash Flows From Operating Activities    
Net loss $ (88) $ (20,394)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 954 2,206
Interest accretion expense 92 123
Amortization of deferred financing fees 42 45
Stock-based compensation 501 1,133
ESPP expense 46
Goodwill impairment 8,433
Intangible asset impairment 3,827
Change in fair value of note payable 400 46
Mark to market on warrants (71)
Change in fair value of contingent consideration (311)
Other changes in operating assets and liabilities:    
Accounts receivable 202 107
Other current assets 176 (45)
Operating lease right of use assets 461
Other long-term assets (1)
Accounts payable 228 (447)
Accrued salaries and bonus (157) (1,312)
Other accrued expenses (118) (914)
Operating lease liabilities (292)
Other long-term liabilities 248 113
Net cash provided by (used in) operating activities 2,649 (7,416)
Cash Flows From Investing Activity    
Proceeds from sale of Interpace Pharma Solutions, net 500 7,431
Working capital adjustment on sale of Interpace Pharma Solutions (117)
Purchase of property and equipment (328) (126)
Net cash provided by investing activities 55 7,305
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 106
Proceeds from convertible debt 2,000
(Payments) borrowings on line of credit (2,500) 1,000
Net cash (used in) provided by financing activities (2,500) 3,106
Net increase in cash, cash equivalents and restricted cash 204 2,995
Cash, cash equivalents and restricted cash from continuing operations– beginning 4,828 2,922
Cash, cash equivalents and restricted cash from discontinued operations– beginning 392
Cash, cash equivalents and restricted cash – beginning 4,828 3,314
Cash, cash equivalents and restricted cash from continuing operations– ending 5,032 6,309
Cash, cash equivalents and restricted cash from discontinued operations– ending
Cash, cash equivalents and restricted cash – ending $ 5,032 $ 6,309